BCC: Point-of-care diagnostics market on the rise
Watch for the global market for point-of-care diagnostics to jump 3.7 percent by 2016, from $13.8 billion to $16.5 billion.
That’s according to a market research report from BCC Research of Wellesley, Mass., which breaks the market into 10 segments—glucose monitoring, blood chemistry and electrolyte, pregnancy and fertility, cardiac markers, drug and alcohol, infectious disease, cholesterol, hemoglobin/hemostasis, urine chemistry and tumor marker.
Cardiac markers represent the fastest-growing segment. BCC projected it to swell at a compound annual growth rate of 14.4 percent, from $1 billion in 2011 to $2 billion in 2016.
BCC noted in a statement that the U.S. is the world’s largest single market for diagnostic testing, adding that point-of-care testing is expanding in both home use and “near-patient” settings. The firm defines point-of-care testing as “any screening or diagnostic test that is performed outside the main hospital laboratory.”
“Over the last decade, more diagnostic tests have been performed at patients’ bedsides in hospitals, physicians’ office laboratories, outpatient clinics, emergency rooms and intensive-critical-care units,” BCC pointed out in the release. “The wider availability of [point-of-care] testing has revolutionized the continuum of the patient-care process by providing laboratory results rapidly and efficiently at these locations.”
BCC concluded by citing several other reasons for the high demand of point-of-care testing, including staff shortages, older populations, long-term cost savings and rural locations without conventional laboratory services.
That’s according to a market research report from BCC Research of Wellesley, Mass., which breaks the market into 10 segments—glucose monitoring, blood chemistry and electrolyte, pregnancy and fertility, cardiac markers, drug and alcohol, infectious disease, cholesterol, hemoglobin/hemostasis, urine chemistry and tumor marker.
Cardiac markers represent the fastest-growing segment. BCC projected it to swell at a compound annual growth rate of 14.4 percent, from $1 billion in 2011 to $2 billion in 2016.
BCC noted in a statement that the U.S. is the world’s largest single market for diagnostic testing, adding that point-of-care testing is expanding in both home use and “near-patient” settings. The firm defines point-of-care testing as “any screening or diagnostic test that is performed outside the main hospital laboratory.”
“Over the last decade, more diagnostic tests have been performed at patients’ bedsides in hospitals, physicians’ office laboratories, outpatient clinics, emergency rooms and intensive-critical-care units,” BCC pointed out in the release. “The wider availability of [point-of-care] testing has revolutionized the continuum of the patient-care process by providing laboratory results rapidly and efficiently at these locations.”
BCC concluded by citing several other reasons for the high demand of point-of-care testing, including staff shortages, older populations, long-term cost savings and rural locations without conventional laboratory services.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.